Abstract 845P
Background
There are growing concerns that current treatments for r/r B-cell NHL and MM are increasing the incidence of SPMs. While on-going clinical trial data suggest that SPM incidence is within the expected range, available SPM incidence benchmarks are unstable due to small numbers. We estimated the incidence rates (IR) of SPMs in r/r B-cell NHL and MM using the Cancer Analysis System (CAS), a population-level cancer database in England for patients diagnosed from 2013-2018.
Methods
R/r disease status was proxied by initiation of second line treatment using a line of therapy (LoT) algorithm. IRs of SPMs in r/r patients were calculated per 1,000 person-years at risk (PYAR) and stratified by age, sex, ethnicity, and year of diagnosis. SPMs were also summarized by type (e.g., solid, haematological, MDS). Preliminary results are rounded per masking requirements.
Results
Of the eligible population, 20% (N=9480) of B-cell NHL patients and 40% (N=5260) of MM patients were identified as r/r based on the LoT algorithm. The median (IQR) age at r/r disease for NHL and MM patients was 68 (58-75) and 69 (60-77), respectively. Most patients were white (90%) and male (60%), with a median follow up time from r/r disease of approximately 17 (6-31) months in NHL patients, and 16 (7-30) months in MM patients. Almost 5% of r/r NHL and 2% of r/r MM patients developed at least one SPM on or after the r/r disease date. The absolute IR of SPMs was 17 (95% CI: 15-19) and 11 (9-14) per 1000 PYAR in r/r NHL and MM patients, respectively. The rate of SPMs increased with diagnosis age in both patient cohorts. Individuals who had their initial NHL or MM diagnosis in earlier years had a higher rate of SPMs than those diagnosed more recently. Approximately 65% of NHL and 75% of MM patients who had an SPM after r/r disease were diagnosed with solid tumours.
Conclusions
These results suggest that in this cohort of r/r patients, SPM IR increases with age and that most of the SPMs are solid tumours. To our knowledge, this is one of the first studies that uses real-world data to estimate a population-level background incidence for SPMs in r/r NHL and MM patients, regardless of therapy received.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bristol Myers Squibb.
Funding
Bristol Myers Squibb.
Disclosure
M. Miret, S. Lee, F.E. Vegni: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb. P. Hindocha, L. Cirneanu, C. Lymperopoulou, E. Markov, S. Hitov: Financial Interests, Personal, Full or part-time Employment: IQVIA.